In order to determine if TP5 could reach its target into the cells, we evaluated the capacity of TP5 to decrease the activity of CDK5 using immuno-precipitation and CDK5 activity assay on two GBM cell lines (U251 and LN229). This evidence concerns the gene TMPO and glioblastoma.